https://www.asm.org/modules/mod_image_show_gk4/cache/Science Advisor Slidegk-is-651.jpglink
https://www.asm.org/modules/mod_image_show_gk4/cache/World AIDS Day Bannergk-is-651.pnglink
https://www.asm.org/modules/mod_image_show_gk4/cache/Amy Chang Bannergk-is-651.jpglink
https://www.asm.org/modules/mod_image_show_gk4/cache/2016.Kavli Slide Submitgk-is-651.jpglink
https://www.asm.org/modules/mod_image_show_gk4/cache/Governance Hero Bannergk-is-651.jpglink
0 1 2 3 4
Progress bar
02-12-2016Science Advisor
02-12-2016World AIDS Day
02-12-2016Amy Chang
02-12-2016Kavli Submit
02-12-2016Nominate
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Antibacterial Development Conference
REGISTER

anderson porterDr. Anderson has applied bacteriology and simple chemistry to the development of vaccines against bacterial infections of infancy, particularly bacteria in which the capsular polysaccharide (CP) interferes with phagocytic clearance. Antibody to CP is protective, but the immune response to CP matures slowly. Along with other workers, Dr. Anderson has researched the conjugation of CP to immunogenic carrier proteins, permitting early-life antibody induction. His approach was used for the first "conjugate" vaccines licensed for 2-month-old infants against meningitis and other life-threatening infections by haemophili, meningococci, and pneumococci. The substantial decline in Haemophilus disease prompted the 1996 Lasker Clinical Award and Pasteur Award to Drs. J.B. Robbins, R. Schneerson, D.H. Smith, and Anderson.

Pneumococcus infections of infancy are prevalent and deadly in third-world settings, but conjugate vaccines are too expensive for nations most afflicted. Since 1996, Dr. Anderson has worked with R. Malley, reviving an inexpensive alternative consisting of killed bacteria--technology readily transferable to developing-world manufacturers. This was protective in preclinical testing, partly through an unexpected antibody-independent, CD4+ T lymphocyte-dependent mechanism, mediated through pro-phagocytic activity of the cytokine IL17A and attributable to TLR agonists within the vaccine. Approval for clinical testing is being sought.

TPL_asm2013_SEARCH

91079